# VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

> **NCT06092333** · PHASE2 · RECRUITING · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** VIR-2218 and peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT06092333
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-08-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092333, "VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06092333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*